On Oct. 30, 2020, the U.S. Department of Health and Human Services (HHS) and the U.S. Department of Defense (DOD) jointly announced a $12.7 million contract with InBios International, of Seattle, to expand domestic production capacity for two rapid point-of-care tests for SARS-CoV-2, the virus that causes COVID-19.

This industrial base expansion effort allowed InBios to increase their production capacity to 400,000 units per week by May 2021, a capacity increase of 20 times their current output.